Figure 1
From: Overexpression of CIP2A is associated with poor prognosis in multiple myeloma
CIP2A is overexpressed in MM and is associated with poor prognosis. (a) Cell viability was determined by CCK-8 assay after Dex treatment in MM.1S and MM.1R cells for 24 h. (b) Cell viability was determined by CCK-8 assay after Dex treatment in 8226 and U266 cells for 24 h. (c) CIP2A relative expression determined by QPCR (compared to GAPDH, respectively). *P<0.05. (d) Western blot analysis showing CIP2A expression in different cell lines. The pro-myelocytic cell line HL-60 was used as a positive control. (e) CIP2A relative expression in patient samples (P1–10) determined by QPCR (compared to GAPDH, respectively). HL-60 was used as a positive control. (f) CIP2A relative expression in volunteers (V1–4), determined by QPCR (compared to GAPDH, respectively). HL-60 was used as a positive control. (g) Schematic images of immunohistochemistry staining intensities for CIP2A expression in MM and normal BM tissue. (h) Scores of immunohistochemistry staining for CIP2A expression in different stages of MM. *P<0.05. (i) The distribution of the difference in CIP2A staining (ΔIRS=IRST−IRSN). Immunoreactivity score (IRS) of CIP2A staining was available from 16 pairs of tissues; P-values were calculated with the Wilcoxon test. CIP2A expression was higher in tumor tissues (T) compared with paired adjacent non-tumor tissues (N). IRST, IRS of tumor tissues; IRSN, IRS of non-tumor tissues. *P<0.05. (j) Survival curves of MM patients with low expression versus high expression of CIP2A (P=0.033).
